🇺🇸 FDA
Patent

US 9974868

Octapod iron oxide nanoparticles as high performance T2 contrast agents for magnetic resonance imaging

granted A61KA61K49/06A61K49/08

Quick answer

US patent 9974868 (Octapod iron oxide nanoparticles as high performance T2 contrast agents for magnetic resonance imaging) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon May 17 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue May 22 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 17 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K49/06, A61K49/08, A61K49/1818, A61K49/1833